Treatment(s) already received-None Posts on Medivizor
Navigation Menu

Treatment(s) already received-None Posts on Medivizor

Looking for patients to try a treatment combination for untreated chronic lymphocytic leukemia.

Posted by on May 28, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with previously untreated chronic lymphocytic leukemia (CLL) to try a new treatment combination containing obinutuzumab (Gazyva) or obinutuzumab/bendamustine (Treanda) to shrink the tumor (debulking) before treatment with venetoclax (Venclexta). The main outcome that will be measured is the number...

Read More

Is vascular-targeted photodynamic therapy or active surveillance more effective in the treatment of low-risk prostate cancer?



Posted by on Apr 30, 2019 in Prostate cancer | 0 comments

In a nutshell This study examined if vascular-targeted photodynamic therapy (VTPT), or active surveillance is more effective in the treatment of low-risk prostate cancer. This study concluded that patients who received VTPT were less likely to require radical therapy compared to those who underwent active surveillance.  Some background...

Read More

Looking for patients with hormone-receptor positive breast cancer to test a new treatment combination

Posted by on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of durvalumab (Imfinzi) in combination with standard hormonal treatment for breast cancer (BC). The main outcome will be the response to treatment. The trial is recruiting in Tampa, Florida, US. The details Breast cancer (BC) is one of the most common cancers. It affects bothe...

Read More

Looking for patients with small lymphocytic lymphoma to test acalabrutinib-obinutuzumab combination

Posted by on Apr 22, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona, Jacksonville,...

Read More

Evaluating PCR therapy for previously untreated indolent non-Hodgkin’s lymphoma

Posted by on Mar 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of a new chemotherapy regimen in patients with previously untreated indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated for these patients. Some background There are three common types of painless NHL....

Read More

Looking for children and young adults with Hodgkin lymphoma to test a new treatment.

Posted by on Mar 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is examining the safety and effectiveness of pembrolizumab (Keytruda) in the treatment of children and young adults with classical Hodgkin lymphoma (HL). The main outcome to be measured will be a response to treatment. This trial is recruiting in the Republic of Korea and the United States. The details...

Read More

Searching for patients to try a new combination of treatments for Hodgkin lymphoma.

Posted by on Mar 26, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is investigating the effects of AVD [doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (DTIC)] with brentuximab vedotin (Adcetris) induction chemotherapy, plus nivolumab (Opdivo) for Hodgkin lymphoma (HL). The main outcome to be measured is survival without cancer worsening 3 years after treatment. The details...

Read More

Searching for patients with newly-diagnosed AML to try this new treatment option

Posted by on Mar 15, 2019 in Leukemia | 0 comments

In a nutshell This Phase 3 study is evaluating the safety and effectiveness of midostaurin (Rydapt) combined with chemotherapy for patients with newly-diagnosed acute myeloid leukemia (AML). The main outcome to be measured will be event-free survival at 5 years. The details Previous studies have shown that midostaurin combined with chemotherapy is...

Read More

Searching for patients with previously untreated DLBCL to try this new treatment combination

Posted by on Mar 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is comparing the effectiveness of R-CHOP chemotherapy with or without enzastaurin (Kinenza) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The main outcome to be measured will be overall survival at the end of the study. The details The current standard first-line treatment for DLBCL is R-CHOP...

Read More